Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger

Rallybio Corp

Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.
Severance includes payments for without-cause termination; additional contingent on Candid merger close.
Equity awards remain outstanding and vest per Merger Agreement; exercisable 90 days post-close.
Pending business combination with Candid Therapeutics announced March 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.